Did you know? ROS1 is a gene found in cells that is important for cell growth and survival. In some people, the ROS1 gene begins to mutate or change and may fuse or join with another gene. When this [...]
Innovative decentralized trial aims to increase patient participation and accelerate research for one of the deadliest, under-researched lung cancers SAN CARLOS, CA – June 12, 2025 — GO2 for Lung Cancer (GO2) and the Addario Lung Cancer Medical Institute [...]
Did you know? There are different kinds of changes, called mutations, that can happen in the MET gene. These changes can help cancer grow and spread. One type is called c-MET overexpression. This means the cancer cells make too [...]
Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer Question: Why does it take so long for the FDA to approve new drugs? Answer: Whenever a new cancer drug is created, it [...]
Question: My doctor told me that I had EGFR-positive lung cancer. How can I learn more about this biomarker type? Answer: EGFR epidermal growth factor receptor is a gene found in cells. It is important because it sends the [...]
By Renee Botello, MSc, Treatment and Trials Navigator Palliative care is an area of medicine that focuses on treating the person by managing the symptoms or problems caused by a disease and/or its treatment. By recognizing health problems and [...]
By Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer This blog post kicks off our series, "Understanding Lung Cancer," which simplifies the science behind lung cancer. Our goal is to provide a deeper understanding [...]
On December 27, 2024, the U.S. Food and Drug Administration (FDA) approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for subcutaneous injection, commonly known as a shot. This approval included all the same uses of Opdivo (nivolumab) that the FDA previously approved [...]
On Dec. 18, 2024, the U.S. Food and Drug Administration (FDA) approved Ensacove (ensartinib) for people with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have an ALK mutation and have not previously received an ALK-targeted therapy. [...]
On Dec. 4, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Bizengri (zenocutuzumab-zbco) for people with metastatic non-small cell lung cancer (NSCLC) who have an NRG1 mutation following progression on or after prior systemic therapy. [...]